Пређи на садржај

Desvenlafaksin

С Википедије, слободне енциклопедије
Desvenlafaksin
Klinički podaci
Prodajno imePristiq, Zyven-OD
Drugs.comMonografija
Način primeneOralno
Farmakokinetički podaci
Poluvreme eliminacije11,1 h
IzlučivanjeRenalno
Identifikatori
CAS broj93413-62-8 Зелена квачицаДа
ATC kodN06AX23 (WHO)
PubChemCID 125017
DrugBankDB06700 Зелена квачицаДа
ChemSpider111300 Зелена квачицаДа
ChEMBLCHEMBL1118 Зелена квачицаДа
Hemijski podaci
FormulaC16H25NO2
Molarna masa263,375
  • CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
  • InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3 Зелена квачицаДа
  • Key:KYYIDSXMWOZKMP-UHFFFAOYSA-N Зелена квачицаДа

Desvenlafaksin je organsko jedinjenje, koje sadrži 16 atoma ugljenika i ima molekulsku masu od 263,375 Da.[1][2][3][4][5][6][7][8][9][10][11][12][13][14]

Osobine

[уреди | уреди извор]
Osobina Vrednost
Broj akceptora vodonika 3
Broj donora vodonika 2
Broj rotacionih veza 4
Particioni koeficijent[15] (ALogP) 2,8
Rastvorljivost[16] (logS, log(mol/L)) -3,2
Polarna površina[17] (PSA, Å2) 43,7

Reference

[уреди | уреди извор]
  1. ^ Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S: Assessment of Infant Dose Through Milk in a Lactating Woman Taking Amisulpride and Desvenlafaxine for Treatment-Resistant Depression. Ther Drug Monit. 5. Ilett, K. F.; Watt, F.; Hackett, L. P.; Kohan, R.; Teoh, S. (2010 Oct). „Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression”. Therapeutic Drug Monitoring. 32 (6): 704—707. PMID 20926994. doi:10.1097/FTD.0b013e3181f88f70.  Проверите вредност парамет(а)ра за датум: |date= (помоћ)
  2. ^ Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. Kamath, J.; Handratta, V. (децембар 2008). „Desvenlafaxine succinate for major depressive disorder: A critical review of the evidence”. Expert Review of Neurotherapeutics. 8 (12): 1787—97. PMID 19086875. doi:10.1586/14737175.8.12.1787. 
  3. ^ Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ: Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. Kornstein, S. G.; Jiang, Q.; Reddy, S.; Musgnung, J. J.; Guico-Pabia, C. J. (август 2010). „Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder”. The Journal of Clinical Psychiatry. 71 (8): 1088—96. PMID 20797382. doi:10.4088/JCP.10m06018blu. 
  4. ^ Liebowitz MR, Tourian KA: Efficacy, Safety, and Tolerability of Desvenlafaxine 50 mg/d for the Treatment of Major Depressive Disorder:A Systematic Review of Clinical Trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. Liebowitz, M. R.; Tourian, K. A. (2010). „Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/D for the treatment of major depressive disorder:a systematic review of clinical trials”. Primary Care Companion to the Journal of Clinical Psychiatry. 12 (3). PMC 2947544 Слободан приступ. PMID 20944767. doi:10.4088/PCC.09r00845blu. 
  5. ^ Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. Mason, J. N.; Deecher, D. C.; Richmond, R. L.; Stack, G.; Mahaney, P. E.; Trybulski, E.; Winneker, R. C.; Blakely, R. D. (новембар 2007). „Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter”. The Journal of Pharmacology and Experimental Therapeutics. 323 (2): 720—9. PMID 17673606. doi:10.1124/jpet.107.125716. . Epub 2007 Aug 2.
  6. ^ Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA: Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol. Montgomery, S. A.; Fava, M.; Padmanabhan, S. K.; Guico-Pabia, C. J.; Tourian, K. A. (новембар 2009). „Discontinuation symptoms and taper/Poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder”. International Clinical Psychopharmacology. 24 (6): 296—305. PMID 19779354. doi:10.1097/YIC.0b013e32832fbb5a. 
  7. ^ Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L: Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome p450 and p-glycoprotein activities. Psychopharmacol Bull. 2009;Oganesian, A.; Shilling, A. D.; Young-Sciame, R.; Tran, J.; Watanyar, A.; Azam, F.; Kao, J.; Leung, L. (2009). „Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities”. Psychopharmacology Bulletin. 42 (2): 47—63. PMID 19629022. 
  8. ^ Pae CU, Park MH, Marks DM, Han C, Patkar AA, Masand PS: Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr Opin Investig Drugs. Pae, C. U.; Park, M. H.; Marks, D. M.; Han, C.; Patkar, A. A.; Masand, P. S. (јануар 2009). „Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause”. Current Opinion in Investigational Drugs (London, England : 2000). 10 (1): 75—90. PMID 19127490. 
  9. ^ Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. Reddy, S.; Kane, C.; Pitrosky, B.; Musgnung, J.; Ninan, P. T.; Guico-Pabia, C. J. (јануар 2010). „Clinical utility of desvenlafaxine 50 mg/D for treating MDD: A review of two randomized placebo-controlled trials for the practicing physician”. Current Medical Research and Opinion. 26 (1): 139—50. PMID 19919295. doi:10.1185/03007990903408678. 
  10. ^ Wyeth Laboratories Inc. Pristiq (desvenlafaxine succinate) extended-release tablets prescribing information. Philadelphia, PA; 2010 Sept.
  11. ^ Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. Pae, Chi-Un (децембар 2011). „Desvenlafaxine in the treatment of major depressive disorder”. Expert Opinion on Pharmacotherapy. 12 (18): 2923—8. PMID 22098230. doi:10.1517/14656566.2011.636033. ..
  12. ^ Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI: Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. Preskorn, Sheldon; Patroneva, Albena; Silman, Heather; Jiang, Qin; Isler, Jennifer A.; Burczynski, Michael E.; Ahmed, Saeeduddin; Paul, Jeffrey; Nichols, Alice I. (фебруар 2009). „Comparison of the Pharmacokinetics of Venlafaxine Extended Release and Desvenlafaxine in Extensive and Poor Cytochrome P450 2D6 Metabolizers”. Journal of Clinical Psychopharmacology. 29 (1): 39—43. PMID 19142106. doi:10.1097/JCP.0b013e318192e4c1. ..
  13. ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126. 
  14. ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958. 
  15. ^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o. 
  16. ^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t. 
  17. ^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e. 

Literatura

[уреди | уреди извор]

Spoljašnje veze

[уреди | уреди извор]


Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).
Преузето из „https://sr.wikipedia.org/w/index.php?title=Desvenlafaksin&oldid=30640616”